Q-omics provides the consensus-scored BMS1P9 profile across patient tissues and cancer cell-line models. BMS1P9 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, BMS1P9 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, BMS1P9 RNA expression shows 5,547 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight KIRC, HNSC, and STAD as cancer lineages where BMS1P9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for BMS1P9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes BMS1P9 survival associations across molecular data types. BMS1P9 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible BMS1P9 RNA expression–survival associations across cancer types. High BMS1P9 expression shows unfavorable associations in KIRC, DLBC, LIHC and ACC, but favorable associations in SKCM and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for BMS1P9 RNA expression.
This table summarizes BMS1P9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for BMS1P9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. BMS1P9 shows lower tumor expression in HNSC, KICH, BRCA, STAD and THCA and higher tumor expression in KIRC. The HNSC box plot shows higher BMS1P9 RNA expression in normal versus tumor tissue (log2 FC = −0.089, t-test p = .003).
This table shows molecular features associated with BMS1P9 in patient tissues and cancer cell lines. In patient samples, BMS1P9 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
